News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 397–432
- Matches
- 6949
- Sources here
- 17
- Companies here
- 35
Search results
Stored financial headlines
Active search
6949 matching headlines
Ticker or company: GENMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Legend Biotech (NASDAQ: LEGN) targets 19.1M new stock awards
Legend Biotech Corporation (LEGN) will hold its Annual General Meeting on September 24, 2026, to vote on several key proposals, including a significant increase in its equity reserve. The company is seeking shareholder approval to boost its 2020 Restricted Shares Plan by 19.1 million …
LEGN
main company
Sharemaestro market context
Price below Trend Line
52 weeks -42.7%
General Fusion heats plasma to 8.4 million degrees toward fusion power
General Fusion (NASDAQ: GFUZ) has released its first public business update since listing on Nasdaq in July 2026, announcing approximately US$150 million in cash to fund its Lawson Machine 26 (LM26) program through 2028. The company reported achieving plasma heating of 0.72 keV (8.4 …
GFUZ
main company
Sharemaestro market context
Stored weekly price path
6 weeks -10.9% · Next-week setup negative 29.2%
S&P downgrades Emergent BioSolutions outlook on competition
S&P Global Ratings has downgraded Emergent BioSolutions Inc.'s outlook to negative from stable due to increased competition in the naloxone market, which led to reduced revenue guidance. The ratings agency projects a significant decline in both its commercial and Medical Countermeasures segments' revenue for …
EBS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -50.3% · Next-week setup negative 43.4%
BBVA: Capital Returns And Turkey Exposure Will Shape Fairly Balanced Future Risk Reward
BBVA's fair value estimate has increased to €22.99, influenced by both rising price targets from some banks and caution from others regarding valuation and Turkey-related risks. While some analysts praise BBVA's strong fundamentals and high RoTE, others have downgraded ratings due to the recent …
BBVA
main company
Sharemaestro market context
Trend signal active
52 weeks +57.5% · Next-week setup positive 65.1%
Las perspectivas alcistas para Amgen (AMGN) podrían cambiar tras la revisión al alza de las previsiones de beneficios para 2026 y los resultados del segundo trimestre, que han superado las expectativas: descubre por qué
AMGN
main company
Sharemaestro market context
Trend signal active
52 weeks +66.3%
The Bull Case For Amgen (AMGN) Could Change Following Raised 2026 Earnings Guidance And Q2 Beat - Learn Why
Amgen Inc. recently reported strong second-quarter 2026 results, with revenues of US$10,054 million and net income of US$2,375 million, leading to raised full-year 2026 guidance. The company now expects total revenue between US$38.20 billion and US$39.40 billion, and GAAP EPS of US$15.80 to US$17.08. …
AMGN
main company
Sharemaestro market context
Trend signal active
52 weeks +44.4%
Ocugen Inc. stock falls Tuesday, underperforms market
Ocugen Inc. (OCGN) shares fell 2.55% on Tuesday, closing at $1.34, significantly underperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines. The company's stock is currently 50.83% below its 52-week high of $2.73, achieved in March.
OCGN
main company
Sharemaestro market context
Price below Trend Line
52 weeks +33.7%
Generation Income Properties (GIPR) holder First City reports 37K-share stake
First City Investment Group, LLC has filed an amended Schedule 13G/A, disclosing its beneficial ownership of 37,153 shares of Generation Income Properties (GIPR) common stock. This stake represents 2.0% of the total outstanding shares, based on 1,861,303 shares as of August 14, 2026. First …
GIPR
main company
Sharemaestro market context
Price below Trend Line
52 weeks -94.8% · Next-week setup negative 41.0%
Legence Corp. Announces Appointment of Robert Crisci as Class II Director and Member of Audit Committee and Nomination and Corporate Governance Committee, Effective August 18, 2026
Legence Corp. has appointed Robert Crisci as a Class II director to its Board, effective August 18, 2026, increasing the Board's size from six to seven directors. Crisci will also serve on the Audit Committee and Nomination and Corporate Governance Committee. He brings extensive …
LGN
main company
Sharemaestro market context
Price below Trend Line
49 weeks +117.6% · Next-week setup positive 63.2%
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up
argenx SE ARGX announced positive top-line data from the phase III ALKIVIA study evaluating Vyvgart Hytrulo, the subcutaneous formulation of its blockbuster therapy, Vyvgart (efgartigimod alfa and hyaluronidase-qvfc) to support a label expansion in adults with autoimmune myositis. Shares rose 16% on Monday following …
Sharemaestro market context Trend signal active 52 weeks +29.0% · Next-week setup positive 56.3%CCC Intelligent (NYSE: CCC) investor to sell 368,930 shares
Brian J. Herb, an investor in CCC Intelligent Solutions Holdings Inc. (NYSE: CCC), intends to sell 368,930 shares of common stock, valued at approximately $2.49 million, following a stock option exercise expected on August 18, 2026. This sale is being conducted under Rule 144, …
CCC
main company
Sharemaestro market context
Price above Trend Line
52 weeks -29.6%
Forget AI Stocks: Value Investing Giant Seth Klarman Is Loading Up on Genuine Parts (GPC)
While investors continue chasing artificial-intelligence stocks, value investor Seth Klarman appears to be making a very different bet.Klarman's Baupost Group increased its position in Genuine Parts Company (NYSE: GPC) by 89% in the second quarter, ending June with 2.82 million shares worth about $332.3 …
GPC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +0.3%
MYGN Maintained by Stephens & Co. -- Price Target Lowered to $3.
Stephens & Co. analyst Mason Carrico has maintained an "Equal-Weight" rating for Myriad Genetics (MYGN) but lowered its price target from $5.00 to $3.00, a 40% reduction. This reflects growing concerns about the company's financial performance, despite GuruFocus indicating the stock is 73.9% undervalued …
MYGN
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.7%
NexGen Energy in talks with BHP over Saskatchewan uranium project, Reuters reports
NexGen Energy is actively discussing its Rook I uranium project in Saskatchewan with BHP, aiming to raise $1 billion for construction. While NexGen's market capitalization has doubled, making an acquisition by BHP potentially more expensive, both companies maintain an open dialogue regarding technical information …
NXE
main company
Sharemaestro market context
Price below Trend Line
52 weeks +46.3%
EVGN: Q2 net loss down 62% year-over-year as AI-driven focus delivers operational and financial gains
Evogene Ltd. (EVGN) has reported a significant 62% year-over-year reduction in its Q2 net loss, attributed to its transformation into an AI-driven company. The company achieved substantial cost reductions and operational milestones, making strong progress in pharma and ag collaborations. Evogene also maintains disciplined …
EVGN
main company
Sharemaestro market context
Price below Trend Line
52 weeks -54.0% · Next-week setup negative 36.4%
Argenx's Myositis Data Strengthen Efgartigimod Outlook, Morgan Stanley Says
Argenx's (ARGX) latest myositis data strengthened the outlook for efgartigimod, particularly in immune-mediated necrotizing myopathy, resulting in higher probability-of-success assumptions, Morgan Stanley said in a report Tuesday.Efgartigimod produced a 15.4-point Silver Upgrade to read this MT Newswires article and get so much more. A …
Sharemaestro market context Trend signal active 52 weeks +23.7% · Next-week setup negative 39.6%Earnings call transcript: Evogene narrows Q2 2026 loss as shares fall 7.8%
Evogene (EVGN) announced its Q2 2026 earnings on August 14, 2026, reporting an EPS of -$0.14, surpassing analyst estimates of -$0.27. The company's quarterly revenue reached $0.35 million, also exceeding the estimated $0.33 million. Evogene's next earnings report is anticipated for Tuesday, August 18, …
EVGN
main company
Sharemaestro market context
Price below Trend Line
52 weeks -54.0% · Next-week setup negative 36.4%
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue PISCATAWAY, N.J., Aug. 18, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while …
1548
main company
Sharemaestro market context
Trend signal active
52 weeks +34.3%
CCOI Shareholder Alert: September 21, 2026 Lead Plaintiff Deadline in Cogent Communications Holdings, Inc. Securities Class Action - Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for Cogent Communications Holdings, Inc. (NASDAQ: CCOI) investors, announcing a lead plaintiff deadline of September 21, 2026, for a securities class action lawsuit. The complaint alleges that Cogent made materially false or misleading statements regarding …
CCOI
main company
Sharemaestro market context
Price below Trend Line
52 weeks -70.4%
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) who suffered losses during the class period of August 1, 2025, to May 15, 2026. The lawsuit alleges that Regeneron made false and misleading statements regarding its …
REGN
main company
Sharemaestro market context
Price above Trend Line
52 weeks +36.8%